The Ministry of Health and Community Protection has warned against nutritional supplements that contain unannounced substances that may cause heart problems and strokes, calling on all health care practitioners in the private health sector to take the necessary steps regarding these products.
The Ministry issued a circular to all health facilities and health-care practitioners in the private sector, warning against the use of the food supplement «Gold Max Pink Capsules», because it contains an undeclared drug substance, sildenafil, which may cause a sharp drop in blood pressure reaching To a dangerous level, and it can pose a great danger to patients with heart disease, diabetes or an increase in the percentage of fats, especially those who take medicines containing nitrates.
In another circular, the ministry warned against using "Super Slim Green Lean Body Capsules" nutritional supplements, because it contained an unspoken medicinal substance, sibutramine, which was withdrawn from the market in October 2010, because it causes heart problems and strokes, noting that The product is not registered with the Ministry of Medicines at the Ministry, and it recommended that necessary measures be taken to withdraw the product from the market and prevent its circulation and import, and in case of any side effects the Ministry recommends reporting.
In a third circular, the Ministry directed the withdrawal of three medical preparations (Penicillin G Penicillin G sodium 10,000,000 unit / vial) for the manufacturer (Fresenius Kabi Canada LTD), and the reason for the withdrawal came as a result of the possible breakage of the Vials packages mentioned - 305609 - 305610 - 305873, and the product is not registered with the drug administration at the Ministry, and the health committee recommended that the necessary measures be taken to withdraw the operations of the said medical product if it is available in the facilities.
The ministry added a warning to a pharmaceutical product produced by F. Hofmann - La Roche Ltd, which is used as a medicine for cancer treatment, and the warning came because patients with partial or complete dihydropyridine dihydrogen and DPD are at risk of increasing severe toxicity during fluoroperidine treatment - (5-FU, capicitapine and tigapur).
The ministry explained that the product is registered with its drug administration, and recommended that the phenotype and genotype be tested before starting fluvirimidine treatment, and that medicines containing FU-5 or capsaicapin and tigapur are prohibited in patients with a complete lack of DPD, and the necessity of prescribing a low dose initially for patients with Partial deficiency of DPD, and therapeutic drug control (TDM) of fluorouracil may improve clinical outcomes in patients receiving FU by continuous intravenous infusion.